| Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ... New England Journal of Medicine 381 (17), 1632-1643, 2019 | 1239 | 2019 |
| Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer S Kopetz, J Desai, E Chan, JR Hecht, PJ O'Dwyer, D Maru, V Morris, ... Journal of clinical oncology 33 (34), 4032, 2015 | 730 | 2015 |
| Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study VK Morris, ME Salem, H Nimeiri, S Iqbal, P Singh, K Ciombor, B Polite, ... The Lancet Oncology 18 (4), 446-453, 2017 | 383 | 2017 |
| Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes JM Loree, AAL Pereira, M Lam, AN Willauer, K Raghav, A Dasari, ... Clinical Cancer Research 24 (5), 1062-1072, 2018 | 313 | 2018 |
| Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment MP Morelli, MJ Overman, A Dasari, SMA Kazmi, T Mazard, E Vilar, ... Annals of Oncology 26 (4), 731-736, 2015 | 280 | 2015 |
| Clinical and molecular characterization of early‐onset colorectal cancer AN Willauer, Y Liu, AAL Pereira, M Lam, JS Morris, KPS Raghav, ... Cancer 125 (12), 2002-2010, 2019 | 275 | 2019 |
| ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper A Dasari, VK Morris, CJ Allegra, C Atreya, AB Benson III, P Boland, ... Nature reviews Clinical oncology 17 (12), 757-770, 2020 | 265 | 2020 |
| Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation DS Hong, VK Morris, B El Osta, AV Sorokin, F Janku, S Fu, MJ Overman, ... Cancer discovery 6 (12), 1352-1365, 2016 | 234 | 2016 |
| Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge CM Parseghian, JM Loree, VK Morris, X Liu, KK Clifton, S Napolitano, ... Annals of Oncology 30 (2), 243-249, 2019 | 195 | 2019 |
| Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). S Kopetz, SL McDonough, VK Morris, HJ Lenz, AM Magliocco, CE Atreya, ... Journal of Clinical Oncology 35 (4_suppl), 520-520, 2017 | 195 | 2017 |
| Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) S Kopetz, KA Guthrie, VK Morris, HJ Lenz, AM Magliocco, D Maru, Y Yan, ... Journal of Clinical Oncology 39 (4), 285, 2021 | 182 | 2021 |
| Treatment of metastatic colorectal cancer: ASCO guideline VK Morris, EB Kennedy, NN Baxter, AB Benson III, A Cercek, M Cho, ... Journal of clinical oncology: official journal of the American Society of …, 2023 | 145 | 2023 |
| Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer V Morris, MJ Overman, ZQ Jiang, C Garrett, S Agarwal, C Eng, B Kee, ... Clinical colorectal cancer 13 (3), 164-171, 2014 | 142 | 2014 |
| Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer MS Lee, EJ McGuffey, JS Morris, G Manyam, V Baladandayuthapani, ... British journal of cancer 114 (12), 1352-1361, 2016 | 97 | 2016 |
| Association between KRAS mutation and lung metastasis in advanced colorectal cancer AAL Pereira, JFM Rego, V Morris, MJ Overman, C Eng, CR Garrett, ... British journal of cancer 112 (3), 424-428, 2015 | 95 | 2015 |
| Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). S Kopetz, SL McDonough, HJ Lenz, AM Magliocco, CE Atreya, LA Diaz, ... Journal of Clinical Oncology 35 (15_suppl), 3505-3505, 2017 | 82 | 2017 |
| Comprehensive genomic profiling of metastatic squamous cell carcinoma of the anal canal V Morris, X Rao, C Pickering, WC Foo, A Rashid, K Eterovic, T Kim, ... Molecular Cancer Research 15 (11), 1542-1550, 2017 | 69 | 2017 |
| Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer K Ludford, R Cohen, M Svrcek, WC Foo, R Colle, Y Parc, JV Thomas, ... JNCI: Journal of the National Cancer Institute 113 (2), 208-211, 2021 | 67 | 2021 |
| FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma K Korphaisarn, VK Morris, MJ Overman, DR Fogelman, BK Kee, ... Oncotarget 8 (24), 39268, 2017 | 65 | 2017 |
| MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon K Raghav, V Morris, C Tang, P Morelli, HM Amin, K Chen, GC Manyam, ... Oncotarget 7 (34), 54627, 2016 | 60 | 2016 |
